by University of Michigan Credit: Pixabay/CC0 Public Domain A recently developed amino acid compound successfully treats nonalcoholic fatty liver disease in non-human primates—bringing scientists one step closer to the first human treatment for the condition that is rapidly increasing around the world, a study suggests. Researchers at Michigan Medicine developed DT-109, a glycine-based tripeptide, to treat the...
